The availability of new and more effective anti-rejection therapy has succeeded in reducing the incidence of acute cellular rejection in first months post-renal transplant. This in turn has escalated the order of significance of recurrence of primary disease in the renal allograft as a cause for patient morbidity and graft loss during this period. The aim of this review is to survey current literature, identify issues and potential areas for future research related to recurrence of primary disease after renal transplant. Our review of published reports suggests that our current knowledge and practice, related to the management of recurrence of primary disease, are mainly based on non-randomized and uncontrolled case series. The future need for well designed mechanistic as well as therapeutic, controlled and randomized multicenter clinical trials cannot be overemphasized.
- Hemolytic uremic syndrome
- Henoch-Schonlein purpura
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health